Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients

Purpose To assess the activity, safety and treatment patterns of sunitinib in patients with poor-risk metastatic renal cell carcinoma (mRCC). Materials and Methods We retrospectively reviewed the charts of poor risk patients treated with sunitinib from October...

Full description

Bibliographic Details
Main Authors:	Romualdo Barroso-Sousa, Rodrigo R. Munhoz, Milena P. Mak, Leonardo G. Fonseca, Angelo B. S. Fede, Rudinei Diogo Marques Linck, Clovis R. Coelho, Camila M. V. Moniz, Ciro E. Souza, Carlos Dzik
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia 2014-12-01
Series:	International Brazilian Journal of Urology
Subjects:	sunitinib [Supplementary Concept] Carcinoma, Renal Cell Safety
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000600835&lng=en&tlng=en

Similar Items

Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
by: Rafael Corrêa Coelho, et al.

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
by: Pavla Bouchalova, et al.
Published: (2021-09-01)

Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib
by: Leonardo Gomes da Fonseca, et al.
Published: (2014-04-01)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib
by: M'rabti Hind, et al.
Published: (2011-07-01)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
by: Keyvanjah Kiana, et al.
Published: (2012-08-01)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
by: Akihiro Yoshimura, et al.
Published: (2020-09-01)

Potential for use sunitinib in pancreatic neuroendocrine tumors
by: A. A. Markovich, et al.
Published: (2019-06-01)

Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study
by: El-Hadaad Hend Ahmed, et al.
Published: (2015-12-01)

Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas
by: Stefan Küffer, et al.
Published: (2022-09-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinoma
by: Hiroyuki Shikuma, et al.
Published: (2019-11-01)

A significant response to sunitinib in a patient with anaplastic thyroid carcinoma
by: Enrique Grande, et al.
Published: (2013-01-01)

Photochemically-Induced Release of Lysosomal Sequestered Sunitinib: Obstacles for Therapeutic Efficacy
by: Judith Jing Wen Wong, et al.
Published: (2020-02-01)

Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
by: Xinan Sheng, et al.
Published: (2020-03-01)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
by: Cheng-Yuan Gu, et al.
Published: (2021-10-01)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
by: Gaetano Facchini, et al.
Published: (2019-08-01)

Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
by: Se Woong Choi, et al.
Published: (2020-02-01)

Sunitinib for adenocarcinoma of the rete testis: a case report
by: Kezhen Li, et al.
Published: (2024-04-01)

Development and validation of a HPTLC method for analysis of Sunitinib malate
by: Monireh Hajmalek, et al.

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
by: William L. Read, et al.
Published: (2016-10-01)

Sunitinib in pancreatic neuroendocrine tumors. Clinical case
by: A. A. Markovich, et al.
Published: (2019-12-01)

Impact of Sunitinib on Human Thyroid Cancer Cells
by: Jirka Grosse, et al.
Published: (2013-07-01)

SIDE EFFECTS OF SUNITINIB MANIFESTED ON SKIN OF PATIENTS DIAGNOSED WITH RENAL CELL CARCINOMA: CASE-CONTROL STUDY
by: Bojana Petrović, et al.
Published: (2009-10-01)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
by: Maud Maillard, et al.
Published: (2022-09-01)

Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report
by: Alexandra Karadimou, et al.
Published: (2011-08-01)

Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells
by: Miaki Uzu, et al.
Published: (2015-05-01)

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
by: Joan Manel Gasent Blesa, et al.
Published: (2009-12-01)

Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids
by: Atthapol Srimongkol, et al.
Published: (2023-02-01)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
by: Ying-Shou Chen, et al.
Published: (2009-10-01)

Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats
by: Mohammad Nasser Hashemian, et al.
Published: (2017-01-01)

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
by: Theofanis Vasileiadis, et al.
Published: (2019-04-01)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
by: Tomonori Sato, et al.
Published: (2020-12-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
by: Giovanni Luca Gravina, et al.
Published: (2017-01-01)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
by: Bo Peng, et al.
Published: (2017-05-01)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
by: Harrison Sicheng Lin, et al.
Published: (2022-01-01)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
by: Amishi Y. Shah, et al.
Published: (2015-03-01)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
by: Zhu X, et al.
Published: (2021-08-01)